Scarica l'app Stockscreener
199.59
0.02%
-0.03
Dopo l'orario di chiusura:
199.59
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$199.62
Aprire:
$197.54
Volume 24 ore:
221.91K
Relative Volume:
1.01
Capitalizzazione di mercato:
$3.98B
Reddito:
$268.09M
Utile/perdita netta:
$124.45M
Rapporto P/E:
34.21
EPS:
5.8347
Flusso di cassa netto:
$38.05M
1 W Prestazione:
-2.02%
1M Prestazione:
-1.46%
6M Prestazione:
+10.81%
1 anno Prestazione:
+83.56%
Intervallo 1D:
$194.67
$201.42
Intervallo di 1 settimana:
$188.67
$205.87
Portata 52W:
$93.58
$227.92
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
199.59 | 3.98B | 268.09M | 124.45M | 38.05M | 5.8347 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | BofA Securities | Buy |
| 2025-12-09 | Iniziato | Citigroup | Buy |
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Allspring Global Investments Holdings LLC Has $13.65 Million Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
LGND Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past Year - Yahoo Finance
EBIT per share of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceuticals Inc (LGND) - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 467 Shares - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 Shares - MarketBeat
Ligand Pharmaceuticals director Kozarich sells $94k in stock - Investing.com
Planned sales: Ligand Pharmaceuticals (LGND) director trims 467 shares - Stock Titan
Ligand Pharmaceuticals CLO sells $1m in shares - Investing.com
Ligand (NASDAQ: LGND) CLO sells 5,000 shares after exercising stock options - Stock Titan
LGND Technical Analysis & Stock Price Forecast - intellectia.ai
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Board member Todd Davis (PTHS) updates Pelthos stock grants and holdings - Stock Titan
LGND (NASDAQ: LGND) Rule 144 sales — 467 shares on three dates - Stock Titan
Insider Move: John L LaMattina Exercises Options, Realizing $185K At Ligand Pharmaceuticals - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Passes Minervini Trend Template and Growth Screen - chartmill.com
Ligand Pharma CLO Sells $1.03M in Stock | Transaction Details & Company BackgroundNews and Statistics - indexbox.io
Ligand Pharmaceuticals director LaMattina sells $433k in shares By Investing.com - Investing.com India
Ligand Pharmaceuticals director LaMattina sells $433k in shares - Investing.com
Ligand (NASDAQ: LGND) director exercises options, sells 2,161 common shares - Stock Titan
LIGAND PHARMACEUTICALS INCORPORATED (LGND) - MSN
CLO Sells LGND 5,000 Shares for $1.0 Million - AOL.com
Support Test: How correlated is Ligand Pharmaceuticals Incorporated to the S P500Market Risk Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
Q4 2025 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Ligand (LGND) grants CFO stock options and 4,933 RSUs - Stock Titan
Ligand (NASDAQ: LGND) CLO awarded RSUs and stock options - stocktitan.net
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know - Yahoo Finance
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know - The Motley Fool
Vanguard (LGND) reports 0 shares after internal realignment (03/27/2026) - stocktitan.net
Ligand Pharmaceuticals Unveils Two New VPs of Investments, Business Development - Contract Pharma
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team - marketscreener.com
Nordea Investment Management AB Has $10.19 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Arecor receives $500k milestone payment from Ligand as royalty deal delivers - Yahoo Finance UK
Insider Sell: Stephen Sabba Sells Shares of Ligand Pharmaceutica - GuruFocus
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 1,000 Shares of Stock - MarketBeat
Ligand Pharmaceuticals director Sabba sells $207,872 in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals director Sabba sells $207,872 in stock - Investing.com
Ligand Pharmaceuticals (LGND) director sells 1,000 shares, keeps stake - Stock Titan
Ligand Pharmaceuticals (LGND) Receives Updated Price Target from Citigroup | LGND Stock News - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $276.00 at Citigroup - MarketBeat
Ligand Pharmaceuticals (LGND) Receives Target Price Boost from C - GuruFocus
Congress Asset Management Co. Sells 187,248 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Stephen Sabba (NASDAQ: LGND) sells 2,034 shares for $409,851 - Stock Titan
AI Stocks: How does Ligand Pharmaceuticals Incorporated score in quality rankingsWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Tudor Investment Corp ET AL Takes $2.79 Billion Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model - Seeking Alpha
Penn Capital Management Company LLC Trims Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Acuitas Investments LLC Trims Holdings in Ligand Pharmaceuticals Incorporated $LGND - marketbeat.com
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ligand Pharmaceuticals Inc Azioni (LGND) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Reardon Andrew | CLO & Secretary |
Apr 01 '26 |
Option Exercise |
52.27 |
5,000 |
261,350 |
46,382 |
| Reardon Andrew | CLO & Secretary |
Apr 01 '26 |
Sale |
201.24 |
5,000 |
1,006,224 |
41,382 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):